Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes
Authors' conclusion
While there is great interest and motivation toward the use of SGLT2i among people with T1D and the physicians who treat them, there is also a clear understanding of the need for personalization of therapy and support for robust evidence to inform care.
Study context
- Population
- People with T1D and physicians who treat them, multiple Canadian sites, online recruitment
- Participants
- 24 vs 7
- Comparison
- People with T1D vs Physicians
- People with T1Dn = 24
- Physiciansn = 7
- Outcome
- How risks and benefits of SGLT2i are considered by participants with T1D and physicians (themes)
Methodological detailssemi-structured interviews, multicentre, conventional qualitative content analysis
- Semi-structured interviews
- Multicentre
- Conventional qualitative content analysis
Main finding
As reported in the abstract
Major themes
- 'Stay in the safe zone': hesitancy to move beyond established therapeutic boundaries
- 'Feeling the disconnect': divergent lenses between patients and clinicians, tension over who holds expertise in T1D care
- Ongoing efforts to reconcile risk-benefit trade-offs when considering new therapies
- Cautiously optimistic search for a path forward, with anticipation and restraint
- Need for personalization of care (overarching theme)
- Five major themes
Original publication
Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes. Diabet Med. Published 4 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →